Why ImmunityBio Stock Slumped on Monday
Source: Motley Fool
2026-04-06 20:01:34 ET
Cancer-focused biotech ImmunityBio (NASDAQ: IBRX) hasn't been in the good graces of a top regulator lately, and the latest development in that story on Monday was discouraging for investors. Numerous shareholders sold out of the stock to sink it by slightly over 3% that trading session.
That regulator is the U.S. Food and Drug Administration (FDA). In mid-March, it sent ImmunityBio a warning letter stating that the biotech 's recent promotional materials for cancer immunotherapy drug Anktiva were "false or misleading."
Image source: Getty Images.
ImmunityBio Inc.
NASDAQ: IBRX
IBRX Trading
4.94% G/L:
$7.41 Last:
14,011,916 Volume:
$7 Open:
IBRX Latest News
April 09, 2026 07:30:00 am
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
April 08, 2026 06:00:00 pm
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
IBRX Stock Data
$6,497,322,803
300,611,373
0.32%
122
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
